AgomAb
AGMB
AgomAb (AGMB) news
Recent news
Agomab Therapeutics NV - Nov-era phase 2B study expected to enroll about 320 patients globally
AInvest Wire · 2d agoAgomab announces first patient dosed in global Nov-era phase 2B study of ontunisertib in fibrostenosing Crohn's disease
AInvest Wire · 2d agoAgomab Therapeutics NV - Radiological assessment shows trend for fibrotic stricture stabilization during treatment
AInvest Wire · Oct 1, 2026Agomab Therapeutics NV - Favorable safety and tolerability profile maintained through 60 weeks of ontunisertib treatment in FSCD
AInvest Wire · Oct 1, 2026Agomab Therapeutics NV - AGMB-447 shows favorable safety and tolerability profile at 4.5 mg bid in IPF patients
Agomab Therapeutics NV is conducting a Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AGMB-447 in participants with idiopathic pulmonary fibrosis (IPF) and healthy volunteers. The study is a three-part, double-blind, randomized,…
AInvest Wire · Sep 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.